E. Frigerio
Papers
1
Total Citations
60
H-Index
1
About
E. Frigerio is a prominent researcher in pharmaceutical bioanalysis and drug metabolism, with a focus on developing robust analytical methods for quantifying novel therapeutic agents. Their most-cited work, a 2003 study on the quantitation of SU11248 (sunitinib), an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues, has garnered 60 citations. This paper showcases Frigerio’s expertise in liquid chromatography-tandem mass spectrometry (LC-MS/MS) and semi-automated liquid-liquid extraction, providing a critical foundation for understanding the pharmacokinetics of this key cancer drug. By enabling precise measurement of drug distribution in biological tissues, Frigerio’s contributions have advanced preclinical drug development and supported the translation of targeted therapies into clinical use. Their work remains influential in the field of bioanalytical chemistry, offering a model for efficient, high-throughput analysis of kinase inhibitors. Frigerio’s research is essential for students and researchers interested in the intersection of analytical chemistry and oncology, highlighting the importance of rigorous method validation in drug discovery.
Research Focus
Key Achievements
Top Papers
- 1